ITRMF (Iterum Therapeutics) Net Margin %: -2,302.31% (As of Sep. 2025)


What is Iterum Therapeutics Net Margin %?

Iterum Therapeutics ITRMF +18.86% Net Margin % is -2,302.31% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Iterum Therapeutics ranks worse than 91.34% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Iterum Therapeutics's Net Income for the three months ended in Sep. 2025 was $-8.98 Mil. Iterum Therapeutics's Revenue for the three months ended in Sep. 2025 was $0.39 Mil. Therefore, Iterum Therapeutics's net margin for the quarter that ended in Sep. 2025 was -2,302.31%.

The historical rank and industry rank for Iterum Therapeutics's Net Margin % or its related term are showing as below:

ITRMF' s Net Margin % Range Over the Past 10 Years
Min: -278729.73   Med: -8867.2   Max: -5788.58
Current: -6913.08

ITRMF's Net Margin % is ranked worse than
91.34% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs ITRMF: -6913.08

Iterum Therapeutics  (OTCPK:ITRMF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Iterum Therapeutics Net Margin % Related Terms

Iterum Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Net Margin % Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2,302.31

ITRMF vs ENSC, PPCB, REVB: Net Margin % Comparison

For the Biotechnology subindustry, Iterum Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iterum Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's Net Margin % falls into.


Iterum Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Iterum Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-24.774/0
= %

Iterum Therapeutics's Net Margin for the quarter that ended in Sep. 2025 is calculated as

Net Margin=Net Income (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-8.979/0.39
=-2,302.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -2,302.31% mean?
Iterum Therapeutics (ITRMF) has a Net Margin % of -2,302.31% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #865 out of 947 companies in the Biotechnology industry, placing it in the top 91.3%.
Is Iterum Therapeutics' Net Margin % too high?
Iterum Therapeutics' current Net Margin % is -2,302.31%. Based on the distribution chart, Iterum Therapeutics ranks #865 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' Net Margin % compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #865 out of 947 companies for Net Margin %. This places Iterum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current Net Margin % is -2,302.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Net Margin % of -2,302.31%. The current Net Margin % is -2,302.31%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Net Margin % is -2,302.31% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.